AIG
GLUE icon

American International Group’s Monte Rosa Therapeutics GLUE Stock Holding History

American International Group’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-15,246
Closed -$107K – 1092
2024
Q1 		$107K Buy
15,246
+86
+0.6% +$510 ﹤0.01% 2473
2023
Q4 		$85.7K Sell
15,160
-61
-0.4% -$239 ﹤0.01% 2643
2023
Q3 		$72.9K Buy
15,221
+541
+4% +$3.48K ﹤0.01% 2683
2023
Q2 		$101K Buy
14,680
+325
+2% +$2.1K ﹤0.01% 2571
2023
Q1 		$112K Buy
14,355
+285
+2% +$1.98K ﹤0.01% 2405
2022
Q4 		$107K Buy
14,070
+458
+3% +$3.81K ﹤0.01% 2470
2022
Q3 		$111K Buy
13,612
+192
+1% +$1.76K ﹤0.01% 2492
2022
Q2 		$130K Sell
13,420
-922
-6% -$9.26K ﹤0.01% 2438
2022
Q1 		$201K Buy
14,342
+7,932
+124% +$110K ﹤0.01% 2232
2021
Q4 		$131K Buy
6,410
+77
+1% +$1.61K ﹤0.01% 2605
2021
Q3 		$141K Buy
+6,333
New +$182K ﹤0.01% 2631

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

American International Group's GLUE Position: Q2 2024 in Review

American International Group sold out of Monte Rosa Therapeutics (GLUE) in Q2 2024, closing a stake of 15,246 shares — an estimated $107K sold.

American International Group first reported a position in GLUE in Q3 2021 and held it in 11 quarters. The position peaked at $201K in Q1 2022. 74 funds tracked by Wall St. Rank hold GLUE as of Q2 2024.

  • American International Group reported no remaining Monte Rosa Therapeutics position as of Q2 2024 after selling out during the quarter.
  • American International Group sold 15,246 Monte Rosa Therapeutics shares in Q2 2024, an estimated $107K.
  • American International Group first reported a position in Monte Rosa Therapeutics in Q3 2021 and held it in 11 quarters.
  • American International Group's Monte Rosa Therapeutics position peaked at $201K in Q1 2022.
  • 74 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2024.

Based on American International Group's 13F filing for Q2 2024, filed 13 Aug 2024.